MedTrace Logo

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

NCT04547712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2025-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to demonstrate the safety and effectiveness of adaptive DBS (aDBS) for Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DEVICE

Adaptive DBS

Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS

Sponsors & Collaborators

  • MedtronicNeuro

    lead INDUSTRY

Principal Investigators

  • Helen Bronte-Stewart, MD, MSE · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2023-01-12
Completion
2025-05-02
FDA Device
Yes

Countries

  • United States
  • Canada
  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04547712 on ClinicalTrials.gov